Follow Elekta

Visit Elekta.com

Elekta | Focus Magazine

Chilean women with cancer to benefit from advanced treatment technology

In 2018, there were almost 55,000 new cancer cases in Chile and almost 30,00 cancer-related deaths.1 Gynecological, prostate and breast cancers in particular are on the rise in the region. To meet this situation, ONCORAD, a medical technology importer, has collaborated with Clínica Sanatorio Alemán in Concepcion Chile, to bring advanced brachytherapy technology to Chile….

Standardizing cervical cancer brachytherapy in India

Cases of cervical cancer can be found in all parts of the world, but the incidence of the disease is much greater in LMIC’s (low and middle-income countries, e.g., India, Nepal, African nations) than in Western countries. Of GLOBOCAN’s 2018 estimate of 570,000 new cervical cancer cases, 85 percent were diagnosed in LMICs, with half…

Collaboration leads to new options for liver cancer patients

Interstitial brachytherapy’s one-day treatment visit, improved dose coverage and lower radiation exposure to healthy liver tissues were the findings of a recent first-of-its kind study1 that compared interstitial liver brachytherapy (BT) treatments of 85 patients with virtual stereotactic body radiation therapy (SBRT) plans created for the same patients. The comparative analysis, published in Brachytherapy, examined…

Boosting radiotherapy with brachy

Highly targeted, potent radiation doses delivered with interventional radiotherapy – a brachytherapy (BT) “boost” complementary to external beam radiation therapy (EBRT) – can lead to better local tumor control and higher survival rates for a variety of different cancers, according to Professor György Kovács, a radiation oncologist Gemelli-INTERACTS (Rome, Italy). Prof. Kovács reviewed the rationale…

First published study on Venezia brachy applicator demonstrates positive results

In the first published study evaluating the utility and clinical value of Elekta’s VeneziaTM Advanced Gynecological Applicator, investigators at Ludwig Maximillian University of Munich (LMU Munich, Germany) – which has used Venezia since 2017 – showed that the hybrid intracavitary/interstitial (IC/IS) brachytherapy (BT) applicator provides significantly improved dose coverage, while also sparing nearby organs-at-risk in a…

Brachy applicator is ultimate tool for cervical cancers

International data demonstrates the superior efficacy of intracavitary/interstitial brachytherapy. The Venezia applicator is applicable for stages IB, IIA/B, IIIA/B, and IVA and designed to reach the parametrium and vaginal extensions. Potent, highly targeted intracavitary/interstitial 3D image-guided adaptive brachytherapy (IGABT) is gaining increasing acceptance clinically and among national and international societies as the quintessential modality to…

Ohio clinic uses Venezia for treating cervical cancer

A prolific user of high dose rate (HDR) brachytherapy for gynecological indications, University Hospitals Seidman Cancer Center (Cleveland, Ohio) enhanced its brachytherapy capabilities with the acquisition and recent use of Elekta’s Venezia Advanced Gynecological Applicator for the first patients. Venezia is designed to enable clinicians to easily reach the cervix, parametrium and vaginal extensions in…

Venezia offers treatment for advanced cervical cancer

First use of Venezia on European continent – Venezia avoids undesired EBRT boost to bladder and pelvic bones, enables straightforward use of interstitial needles to treat parametrial disease extension – “Clickable” design facilitates applicator insertion Ludwig-Maximillians University of Munich (LMU Munich) and Sana Klinikum Offenbach (Offenbach, Germany) ushered in a new era of precision brachytherapy…